Capecitabine and Pegylated Interferon Alfa-2a in Treating Patients With Recurrent or Progressive Brain Metastases Due to Breast Cancer
Stopped early · Phase 2
Conditions studied: Breast Cancer, Metastatic Cancer
In brief
RATIONALE: Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Pegylated interferon alfa-2a may interfere with the growth of tumor cells. Giving capecitabine together with pegylated interferon alfa-2a may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving capecitabine together with pegylated interferon alfa-2a works in treating patients with recurrent or progressive brain metastases due to breast cancer.
Key facts
- Study ID
- NCT00227656
- Run by
- M.D. Anderson Cancer Center
- People needed
- 2
- Starts
- 2005-09-01
- Expected to finish
- 2006-11-01
- Last updated by the study team
- 2012-12-11
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- CCOP - Wichita — Wichita, Kansas, United States
- CCOP - Grand Rapids — Grand Rapids, Michigan, United States
- Cancer Research for the Ozarks — Springfield, Missouri, United States
- University of Texas M.D. Anderson CCOP Research Base — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.